desmopressin
Trade name: ddavp
Approved
Feb 21, 1978
Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH), which is found naturally in the body and is produced by the hypothalamus and stored, in the posterior pituitary gland. The main function of ADH is to regulate extracellular fluid volume in the body. ADH secretion is stimulated by angiotensin II, linking it to the renin-angiotensin-aldosterone system (RAAS). ADH stimulates water reabsorption in the kidneys by causing the insertion of aquaporin-2 channels on the apical surface of cells of the distal convoluted tubule and collecting tubules. Desmopressin also causes vasoconstriction through its action on vascular smooth muscle cells of the collecting tubules. It increases urine concentration and decreases urine production. Acetate salt of desmopressin is sold under brand name DDAVP with different formulations: DDAVP Nasal Spray is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is ineffective for the treatment of nephrogenic diabetes insipidus. DDAVP Injection is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% and is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. It was suggested that desmopressin-induced relaxation was mediated by a receptor subtype sharing both V1A and V2 pharmacological profiles. — NCATS
Clinical trial activity
90 trials · 66 clinical orgs · 32 marketing orgs
Earliest trial started Jan 1, 2001 (NCT00111215)
Timeline
1990s
- Dec 26, 1990
Ferring — NDA Secondary Org
- Oct 15, 1997
Teva — Marketing Organization
- Oct 15, 1997
Eu Yan Sang — Marketing Organization
- Jan 25, 1999
Bausch Health Companies — Marketing Organization
- Jan 25, 1999
Bausch & Lomb — Marketing Organization
2000s
- Feb 18, 2000
Bedford Pharmaceuticals — Marketing Organization
- Aug 28, 2000
Hospira — Marketing Organization
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2004
- Jan 27, 2005
Apotex — Marketing Organization
- Jul 1, 2005
Actavis — Marketing Organization
- Jan 25, 2006
Impax Laboratories — Marketing Organization
2010s
- Dec 23, 2013
Sun Pharmaceuticals — Marketing Organization
- Jun 27, 2014
Mylan — Marketing Organization
- Jun 27, 2014
Natco Pharma — Marketing Organization
- May 28, 2015
Glenmark Pharmaceuticals — Marketing Organization
- Mar 3, 2017
Avadel Pharmaceuticals — NDA Secondary Org
- Mar 3, 2017
Roivant Sciences, Inc. — Marketing Organization
- Mar 3, 2017
Serenity Pharmaceuticals, Inc. — Marketing Organization
- Mar 3, 2017
Acerus Pharmaceuticals Corporation — Marketing Organization
- Mar 3, 2017
Bausch Health Companies — NDA Secondary Org
- May 26, 2017
Heritage Pharma — Marketing Organization
- May 26, 2017
Emcure — Marketing Organization
- Aug 22, 2017
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Aug 22, 2017
Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization
- Oct 3, 2017
Zydus Discovery DMCC — Marketing Organization
- Jan 28, 2019
Abhai LLC — Marketing Organization
- Feb 14, 2019
Sankyo — Marketing Organization
- Feb 14, 2019
Lutipold — Marketing Organization
- Feb 14, 2019
Daiichi Sankyo — Marketing Organization
- Jun 6, 2019
Novast Labs — Marketing Organization
2020s
- Feb 14, 2020
UBI Pharma Inc. — Marketing Organization
- Aug 19, 2022
Dr. Reddy's Laboratories — Marketing Organization
- Nov 16, 2022
Fosun — Marketing Organization
- Mar 20, 2023
Gland Pharma Ltd — Marketing Organization
Indications
Approved for
Studied for
- Acute Kidney Injury · Phase 3
- Anemia, Sickle Cell · Phase 4
- Aortic Stenosis, Subvalvular · Phase 4
- Atherosclerosis · Phase 1
- Blood Coagulation Disorders · Phase 4
- Blood Loss, Surgical · Phase 4
- Breast Neoplasms · Phase 2
- Cerebral Hemorrhage · Phase 2
- Colorectal Neoplasms · Phase 2
- Cushing Syndrome · Phase 2
- Deamino Arginine Vasopressin · Phase 4
- Diabetes Insipidus, Neurogenic · Phase 3
- Dyspnea · Phase 1
- Enuresis · Phase 4
- General Surgery · Phase 4
- Healthy Volunteers · Phase 1
- Hemophilia A · Phase 4
- Hemorrhage · Phase 4
- Hemostasis · Phase 4
- Hypertension · Phase 1
- Intracranial Arteriosclerosis · Phase 1
- Kidney Diseases · Phase 4
- Kidney Transplantation · Phase 4
- Leptospirosis · Phase 2/Phase 3
- Nocturia · Phase 4
- Nocturnal Enuresis · Phase 4
- Osteoarthritis · Phase 4
- Pain · Phase 3
- Parkinson Disease · Phase 4
- Polyuria · Phase 4
- Postoperative Complications · Phase 2
- Postoperative Hemorrhage · Phase 4
- Prostatic Hyperplasia · Phase 4
- Prostatic Neoplasms, Castration-Resistant · Early Phase 1
- Renal Colic · Phase 3
- Renal Insufficiency · Phase 4
- Renal Insufficiency, Chronic · Phase 3
- Shock · Phase 2
- Sleep Disorders, Intrinsic · Phase 3
- Spondylolisthesis · Phase 4
- Stroke · Phase 2
- Tachycardia · Phase 1
- Urinary Bladder, Overactive · Phase 2
Mechanism of action
Approval history
- approvedPriority reviewFeb 21, 1978
Chemistry & pharmacology
SMILES
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O- Mol. weight
- 1069.24 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL1429 ↗
- WikipediaDesmopressin ↗
- NCATSENR1LLB0FP ↗
- ChEMBLCHEMBL376685 ↗
- ChEMBLCHEMBL1200556 ↗
Also known as
- 1-(3-mercaptopropionic acid)-8-d-arginine-vasopressin
- 1-(3-mercaptopropionic acid)-8-d-arginine-vasopressin
- 1-deamino-8-d-arginine vasopressin
- 1-deamino-8-d-arginine vasopressin
- 1-desamino-8-d-arginine vasopressin
- 1-desamino-8-d-arginine vasopressin
- adiuretin
- concentraid
- concentraid
- ddavp
- ddavp
- ddavp
- ddavp
- ddavp
- ddavp (needs no refrigeration)
- ddavp (needs no refrigeration)
- desmomelt
- desmopresin
- desmopresina
- desmopresina
- desmopressin
- desmopressin
- desmopressin
- desmopressin
- desmopressin
- desmopressin
- desmopressin
- desmopressin
- desmopressin acetate
- desmopressin acetate
- desmopressin acetate
- desmopressin acetate
- desmopressin acetate
- desmopressin acetate hydrate
- desmopressin acetate hydrate
- desmopressin acetate hydrate
- desmopressin acetate hydrate
- desmopressin acetate hydrate
- desmopressin acetate hydrate
- desmopressin acetate (needs no refrigeration)
- desmopressin acetate (needs no refrigeration)
- desmopressine
- desmopressine
- desmopressinum
- desmopressinum
- desmospray
- desmospray
- desmotabs
- desmotabs
- minirin
- minirin
- minirin
- minirin
- minirinmelt
- nocutil
- nocutil
- noqdirna
- octim
- octim
- octostim
- octostim
- presinex
- presinex
- ser120
- stimate
- stimate
- stimate (needs no refrigeration)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07012837 | Phase 3 | Jul 31, 2025 | Imam Abdulrahman Bin Faisal University |
| NCT07292753 | N/A | Dec 15, 2024 | Ain Shams University |
| NCT07199894 | Phase 3 | Dec 1, 2024 | Mansoura University |
| NCT06635629 | Phase 2 | Nov 17, 2024 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT06771128 | N/A | Nov 1, 2024 | Menoufia University |
| NCT06337838 | Phase 3 | Aug 31, 2024 | McMaster University, University of Western Ontario |
| NCT06622187 | Phase 4 | Aug 14, 2024 | Federal University of Health Science of Porto Alegre |
| NCT06255366 | Phase 4 | Mar 28, 2024 | Chengdu University of Traditional Chinese Medicines |
| NCT06285006 | N/A | Feb 23, 2024 | Al Azhar University |
| NCT06772584 | N/A | Jan 1, 2024 | Menoufia University |
| NCT05945420 | Phase 4 | Jul 20, 2023 | Mansoura University |
| NCT06185361 | N/A | Dec 1, 2022 | Cairo University |
| NCT05617664 | N/A | Nov 23, 2022 | Benha University |
| NCT05467033 | Phase 3 | Sep 1, 2022 | Medical University of Bialystok |
| NCT05507476 | N/A | Sep 1, 2022 | Zagazig University |
| NCT05430048 | Phase 2 | Jul 1, 2022 | Zagazig University |
| NCT05399173 | N/A | Jun 2, 2022 | Cairo University |
| NCT04586790 | Phase 2 | Oct 15, 2020 | Assiut University |
| NCT04420585 | Phase 4 | Jul 31, 2020 | Yeshiva University |
| NCT04545931 | Phase 4 | Mar 15, 2020 | Cairo University |
Organizations
Research & Development (66)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ferring | For profit | 20 | 17 | 4 | 2004 |
| Ghent University | Academic/Hospital | 6 | 5 | 1 | 2009 |
| Serenity Pharmaceuticals, Inc. | For profit | 6 | 6 | 1 | 2009 |
| University of Toronto | Academic/Hospital | 4 | 3 | 3 | 2015 |
| Cairo University | Academic/Hospital | 3 | 3 | 2 | 2020 |
| Aarhus University | Academic/Hospital | 2 | 2 | 2 | 2012 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 2 | 1 | 2 | 2003 |
| Laboratorio Elea S.A.C.I.F. y A. | For profit | 2 | 2 | 1 | 2011 |
| Mansoura University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Menoufia University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 1 | 2 | 2013 |
| Tel Aviv University | Academic/Hospital | 2 | 2 | 2 | 2006 |
| The University of Hong Kong | Academic/Hospital | 2 | 2 | 2 | 2009 |
| Yeshiva University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Zagazig University | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Accumetrics, Inc. | For profit | 1 | 0 | 1 | 2009 |
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Al Azhar University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Assiut University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Band Therapeutics | For profit | 1 | 1 | 1 | 2019 |
Marketing (43)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abhai LLC | For profit | MKTG | Jan 28, 2019 |
| Acerus Pharmaceuticals Corporation | For profit | MKTG | Mar 3, 2017 |
| Actavis | For profit | MKTG | Jul 1, 2005 |
| Apotex | For profit | MKTG | Jan 27, 2005 |
| Apotex | For profit | SYN | Jan 27, 2005 |
| Avadel Pharmaceuticals | For profit | NDA2 | Mar 3, 2017 |
| Bausch & Lomb | For profit | MKTG | Jan 25, 1999 |
| Bausch Health Companies | For profit | MKTG | Jan 25, 1999 |
| Bausch Health Companies | For profit | NDA2 | Mar 3, 2017 |
| Bedford Pharmaceuticals | For profit | MKTG | Feb 18, 2000 |
| Daiichi Sankyo | For profit | MKTG | Feb 14, 2019 |
| Dr. Reddy's Laboratories | For profit | MKTG | Aug 19, 2022 |
| Emcure | For profit | MKTG | May 26, 2017 |
| Eu Yan Sang | For profit | MKTG | Oct 15, 1997 |
| Ferring | For profit | SYN | Feb 21, 1978 |
| Ferring | For profit | NDA2 | Dec 26, 1990 |
| Ferring | For profit | NDA | Feb 21, 1978 |
| Fosun | For profit | MKTG | Nov 16, 2022 |
| Gland Pharma Ltd | For profit | MKTG | Mar 20, 2023 |
| Gland Pharma Ltd | For profit | SYN | Nov 16, 2022 |
| Glenmark Pharmaceuticals | For profit | MKTG | May 28, 2015 |
| Heritage Pharma | For profit | MKTG | May 26, 2017 |
| Hospira | For profit | MKTG | Aug 28, 2000 |
| Impax Laboratories | For profit | MKTG | Jan 25, 2006 |
| Lutipold | For profit | MKTG | Feb 14, 2019 |
| Mylan | For profit | SYN | Jun 27, 2014 |
| Mylan | For profit | MKTG | Jun 27, 2014 |
| Natco Pharma | For profit | MKTG | Jun 27, 2014 |
| Nichi-Iko Pharmaceutical Co., Ltd. | For profit | MKTG | Aug 22, 2017 |
| Novast Labs | For profit | MKTG | Jun 6, 2019 |
| Roivant Sciences, Inc. | For profit | MKTG | Mar 3, 2017 |
| Roivant Sciences, Inc. | For profit | MKTG | Mar 3, 2017 |
| Sagent Pharmaceuticals, Inc. | For profit | SYN | Aug 22, 2017 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Aug 22, 2017 |
| Sankyo | For profit | MKTG | Feb 14, 2019 |
| Serenity Pharmaceuticals, Inc. | For profit | MKTG | Mar 3, 2017 |
| Sun Pharmaceuticals | For profit | SYN | Dec 23, 2013 |
| Sun Pharmaceuticals | For profit | MKTG | Dec 23, 2013 |
| Sun Pharmaceuticals | For profit | SYN | Apr 12, 2012 |
| Sun Pharmaceuticals | For profit | SYN | Jan 25, 2013 |
| Teva | For profit | MKTG | Oct 15, 1997 |
| UBI Pharma Inc. | For profit | MKTG | Feb 14, 2020 |
| Zydus Discovery DMCC | For profit | MKTG | Oct 3, 2017 |